Results of Operations and Financial Condition On August 5, 2026, ImageneBio, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities…

Chief Financial Officer — Yanina Grant-Huerta: The company appointed a new Chief Financial Officer from an external candidate.

Senior Vice President of Finance and Operations and principal accounting officer — Robert Lally: Mr. Lally resigned and the company plans to search for a replacement.

Annual board election with no specific departures or appointments mentioned.

Results of Operations and Financial Condition On May 7, 2026, ImageneBio, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities o…

The Company expects to use the net proceeds from the Closing of the Private Placement, together with the Company’s existing cash and cash equivalents, to support late-phase development readiness in atopic dermatitis, expand development of IMG-007 into additional indications, including alopecia areata. The securities described above under

Entry into a Material Definitive Agreement. Securities Purchase Agreement On April 12, 2026, ImageneBio, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue pre-funded warrants to purchase shares of the Company’s voting common stock, par value $0.001 (“Common Stock” and the shares subject to the pre-fund…

Principal Accounting Officer — Erin Butler: Ms. Erin Butler mutually separated from her role as Principal Accounting Officer, and Bob Lally was appointed to the same role.

Results of Operations and Financial Condition On March 10, 2026, ImageneBio, Inc. (the “Company”) announced its financial results for the quarter and fiscal year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subjec…

Director — Steven Hui Wang: Mr. Wang resigned as a member of the Board of Directors without any stated disagreement.

Chief Medical Officer — Yufang Lu, M.D., Ph.D.: Dr. Yufang Lu resigned as Chief Medical Officer.

Results of Operations and Financial Condition On November 12, 2025, ImageneBio, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the lia…

Director and Chair of the Audit Committee — Joseph P. Slattery: The company expanded its board and appointed a new director with specific responsibilities.

Termination of a Material Definitive Agreement. To the extent required by

Entry into a Material Definitive Agreement. On October 23, 2025, we provided written notice (the “Notice”) of our election to (i) not have that certain transition services agreement, dated July 25, 2025 (the “Agreement”) with Miragene Inc., an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands (“Miragene”), automatically renew under the current service terms and (ii) extend the term for six months following the end of the initial term for a…

Chief Executive Officer and interim principal financial officer — Kristin Yarema, Ph.D.: Dr. Kristin Yarema was appointed as the interim principal financial officer in addition to her role as Chief Executive Officer.

CFO — Jotin Marango, M.D., Ph.D.: Dr. Marango resigned as CFO and no successor has been named.

of the Original Report to include Management’s Discussion and Analysis of Financial Condition and Results of Operations of Inmagene (as defined in the Original Report) for the three and six months ended June 30, 2025 and 2024; and (ii) include the unaudited interim condensed financial statements of Inmagene as of and for the three and six months ended June 30, 2025 and 2024 under Item 9.01(a) of the Original Report. This Amendment No. 1 does not amend any other item of the Original Report or…

Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On August 2, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of ImageneBio, Inc. (formerly Ikena Oncology, Inc.) (the “Company”) dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm, with such dismissal to become effective on August 2, 2025 (the “Effective Time”). EY’s audit reports on the Company’s consolidated…

The excerpt is incomplete and does not provide sufficient information to determine the nature of the event.

Other Events. Ikena Oncology, Inc. (“Ikena”) today announced that it will effect a 1-for-12 reverse stock split of Ikena’s common stock, par value $0.001 per share (“Ikena common stock”) that is expected to begin trading on a post-reverse stock split basis on The Nasdaq Capital Market (“Nasdaq”) on July 28, 2025, under the new name “ImageneBio, Inc.”, ticker symbol “IMA”, CUSIP number 45175G207 and ISIN number US45175G2075. The reverse stock split effects all issued and outstanding shares of…

Other Events As previously announced, on December 23, 2024, Ikena Oncology, Inc., a Delaware corporation (“Ikena”), Insight Merger Sub I, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands and direct wholly owned subsidiary of Ikena (“Merger Sub I”), Insight Merger Sub II, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands and direct wholly owned subsidiary of Ikena (“Merger Sub II”),…

Jotin Marango, M.D., Ph.D.: Amendment to employment agreement providing additional benefits in case of termination or resignation during the change in control period.

Other Events. On July 15, 2025, Ikena issued a press release announcing the results of the voting proposals from the Annual Meeting, as well as certain information with respect to the reverse stock split of Ikena common stock. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated herein by reference. Based on the results of the Annual Meeting, the Merger and the Ikena concurrent financing are expected to be consummated around the end of July, subject to the satisfact…

Stockholders approved equity incentive and employee stock purchase plans.